Elicio Therapeutics (ELTX) Debt to Equity (2020 - 2026)

Elicio Therapeutics has reported Debt to Equity for 4 years, with the latest figure at -$6.59 in Q1 2026.

• For the quarter ending Q1 2026, Debt to Equity changed N/A year-over-year to -$6.59; the trailing twelve-month figure through Mar 2026 stood at -$6.59 (changed N/A YoY), and the FY2025 full-year result was $5.75, up 424.67% from the prior year.
• Debt to Equity for Q1 2026 stood at -$6.59, down from $5.75 in the prior quarter.
• The five-year high for Debt to Equity was $5.75 in Q4 2025, with the low at -$6.59 in Q1 2026.
• Historically, Debt to Equity has averaged $1.0 across 3 years, with a median of $2.55 in 2025.
• The largest YoY upside for Debt to Equity was 424.67% in 2025 against a maximum downside of 424.67% in 2025.
• Elicio Therapeutics' Debt to Equity stood at -$1.77 in 2024, then soared by 424.67% to $5.75 in 2025, then plunged by 214.67% to -$6.59 in 2026.
• The last three Debt to Equity figures came in at -$6.59 (Q1 2026), $5.75 (Q4 2025), and $2.55 (Q3 2025), per Business Quant data.